• 1 川北醫(yī)學院病理學教研室（四川南充，637000） ;2瀘州醫(yī)學院病理學教研室;

目的 　通過復制人肝癌細胞株HepG2裸鼠皮下移植瘤模型，觀察綠茶提取物表沒食子兒茶素沒食子酸酯（EGCG）干預對HepG2移植瘤新生血管生成的影響。 方法 　瘤體接種復制HepG2移植瘤模型，荷瘤裸鼠20只隨機分組，實驗組給予EGCG溶液每日20 mg/（kg·只），腹腔注射3周，對照組給予等量滅菌注射用水3周，末次用藥24 h，后處死裸鼠，剝離移植瘤。常規(guī)病理切片觀察移植瘤組織結(jié)構(gòu)；逆轉(zhuǎn)錄-聚合酶鏈式反應(yīng)和免疫組織化學法檢測移植瘤缺氧誘導因子-1α（HIF-1α）、血管內(nèi)皮生長因子（VEGF）mRNA及蛋白表達，并通過檢測CD34表達計數(shù)瘤組織微血管密度（MVD）。 結(jié)果 　組織病理學觀察實驗組移植瘤見大量壞死區(qū)，瘤體內(nèi)血管數(shù)量明顯少于對照組；實驗組HIF-1α、VEGF mRNA及蛋白表達水平比對照組均明顯下調(diào)（P＜0.05），實驗組MVD比對照組明顯下降（P＜0.05）。 結(jié)論 　EGCG可抑制荷瘤裸鼠HepG2移植瘤新生血管生成。

引用本文： 秦姣,肖秀麗,蒲霞. 綠茶提取物表沒食子兒茶素沒食子酸酯對人肝癌細胞株HepG2裸鼠移植瘤新生血管生成的影響. 華西醫(yī)學, 2012, 27(6): 877-881. doi: 復制

版權(quán)信息： ?四川大學華西醫(yī)院華西期刊社《華西醫(yī)學》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 　Larsen CA, Dashwood RH. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide[J]. Biochem Biophys Res Commun, 2009, 389(3): 527-530.
2. 　Zhu BH, Zhan WH, Li ZR, et al. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis[J]. World J Gastroenterol, 2007, 13(8): 1162-1169.
3. 　Farabegoli F, Papi A, Bartolini G, et al. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line[J]. Phytomedicine, 2010, 17(5): 356-362.
4. 　Shankar S, Ganapathy S, Hingorani SR, et al. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer[J]. Front Biosci, 2008, 13(1): 440-452.
5. 　趙麗萍, 邵宛芳. 茶葉中EGCG功效研究進展[J]. 中國農(nóng)學通報, 2007, 23(7): 143-147.
6. 　Suzuki Y, Miyoshi N, Isemura M. Health-promoting effect of green tea[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012,88(3): 88-101.
7. 　 M Chacko S, Thambi PT, Kuttan R, et a1. Beneficial effects of green tea: a literature review[J]. Chin Med, 2010, 5(1): 13.
8. 　Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication[J]. Semin Diagn Pathol, 1993, 10(4): 302-313.
9. 　Zhu BH, Zhan WH, He YL, et al. Epigallocatechin-3-gallate inhibits growth and angiogenesis of gastric cancer and its molecular mechanism[J]. World J gastroenterol, 2009, 12(1): 82-85.
10. 　Wu H, Xin Y, Xiao Y, et al. Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts[J]. Cancer Biother Radiopharm, 2012, 27(3): 204-209.
11. 　Fraga A, Ribeiro R, Medeiros R. Tumor hypoxia: the role of HIF[J]. Actas Urol Esp, 2009, 33(9): 941- 951.
12. 　Nakayama K. Cellular signal transduction of the hypoxia response[J]. J Bio Chem, 2009, 146(6): 757-765.
13. 　Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer[J]. Expert Rev Mol Med, 2009, 27(2): 11- 26.
14. 　Jubb A, Hillan K. Expression of HIF-1 alpha in human tumours[J]. J Clin Pathol, 2005, 58(12): 1344.
15. 　Przybylski M. A review of the current research on the role of bFGF and VEGF in angiogenesis[J]. J Wound Care, 2009, 18(12): 516-519.
16. 　Appelmann I, Liersch R, Kessler T, et a1. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy[J]. Recent Results Cancer Res, 2010, 180(3): 978-998.
  1. 1. 　Larsen CA, Dashwood RH. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide[J]. Biochem Biophys Res Commun, 2009, 389(3): 527-530.
  2. 2. 　Zhu BH, Zhan WH, Li ZR, et al. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis[J]. World J Gastroenterol, 2007, 13(8): 1162-1169.
  3. 3. 　Farabegoli F, Papi A, Bartolini G, et al. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line[J]. Phytomedicine, 2010, 17(5): 356-362.
  4. 4. 　Shankar S, Ganapathy S, Hingorani SR, et al. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer[J]. Front Biosci, 2008, 13(1): 440-452.
  5. 5. 　趙麗萍, 邵宛芳. 茶葉中EGCG功效研究進展[J]. 中國農(nóng)學通報, 2007, 23(7): 143-147.
  6. 6. 　Suzuki Y, Miyoshi N, Isemura M. Health-promoting effect of green tea[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012,88(3): 88-101.
  7. 7. 　 M Chacko S, Thambi PT, Kuttan R, et a1. Beneficial effects of green tea: a literature review[J]. Chin Med, 2010, 5(1): 13.
  8. 8. 　Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication[J]. Semin Diagn Pathol, 1993, 10(4): 302-313.
  9. 9. 　Zhu BH, Zhan WH, He YL, et al. Epigallocatechin-3-gallate inhibits growth and angiogenesis of gastric cancer and its molecular mechanism[J]. World J gastroenterol, 2009, 12(1): 82-85.
  10. 10. 　Wu H, Xin Y, Xiao Y, et al. Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts[J]. Cancer Biother Radiopharm, 2012, 27(3): 204-209.
  11. 11. 　Fraga A, Ribeiro R, Medeiros R. Tumor hypoxia: the role of HIF[J]. Actas Urol Esp, 2009, 33(9): 941- 951.
  12. 12. 　Nakayama K. Cellular signal transduction of the hypoxia response[J]. J Bio Chem, 2009, 146(6): 757-765.
  13. 13. 　Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer[J]. Expert Rev Mol Med, 2009, 27(2): 11- 26.
  14. 14. 　Jubb A, Hillan K. Expression of HIF-1 alpha in human tumours[J]. J Clin Pathol, 2005, 58(12): 1344.
  15. 15. 　Przybylski M. A review of the current research on the role of bFGF and VEGF in angiogenesis[J]. J Wound Care, 2009, 18(12): 516-519.
  16. 16. 　Appelmann I, Liersch R, Kessler T, et a1. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy[J]. Recent Results Cancer Res, 2010, 180(3): 978-998.